DaVita Kidney Care account plan
Kidney care community passion
At a glance
DaVita is a U.S. kidney care and dialysis provider with 2,657 U.S. centers, about 36% market share and FY2025 revenues of $13,643 million.
DaVita Inc. is a comprehensive kidney care provider and a leading U.S. dialysis provider, covering the kidney health journey from chronic kidney disease (CKD) to dialysis and transplant. At December 31, 2025 it ran 2,657 U.S. outpatient dialysis centers in 46 states and DC serving approximately 200,500 patients, had inpatient dialysis contracts with approximately 740 hospitals, and estimated an approximately 36% share of the U.S. dialysis market; it also operates 598 centers in 14 countries. FY2025 consolidated revenues were $13,643 million (+6.5%) and net income attributable to DaVita Inc. $746.8 million. It employs approximately 78,000 teammates, 72% in the U.S.; Berkshire Hathaway holds 45.0% of the shares.
Business units
U.S. dialysis and related lab services
approximately 86% of FY2025 revenues ($11,793 million)Outpatient hemodialysis in 2,657 centers, inpatient dialysis for approximately 740 hospitals, and home dialysis. Revenue per treatment rose to $409.56 in FY2025 while treatments fell 1.1%; government programs provide approximately 68% of revenues, and commercial payors generate nearly all profits.
U.S. Integrated Kidney Care (IKC)
$542 million of FY2025 revenuesIntegrated care management for health plans and government programs covering ESKD and CKD members, through Medicare Advantage C-SNPs, CMMI's CKCC model and shared savings. Approximately 80,800 patients were in risk-based arrangements at September 30, 2026; DaVita expects at least $65 million of IKC adjusted operating income in 2026.
U.S. other ancillary services
$34 million of FY2025 revenuesDaVita Clinical Research, the MedSleuth transplant software business, a medical device company and DaVita Venture Group; operating loss of $(18) million in FY2025.
International dialysis operations
approximately 10% of FY2025 revenues ($1,346 million)598 outpatient centers in 14 countries at Q3 2026, led by Brazil, Colombia, Malaysia, Poland and Chile. Revenues grew 37.8% in FY2025, mainly from acquisitions; a $62 million impairment hit the China business in Q3 2026.
Strategic priorities
- Return to volume growth
- Management targets a path back to 2% or greater treatment volume growth by 2029, through lower mortality and clinical performance; treatments grew 1.2% in Q3 2026 over Q3 2025.
- Expanded hemodialysis rollout
- After pilots in 150 centers for more than 10,000 patients, expanded HD with Nipro dialyzers is offered to the vast majority of eligible patients from November 2026, with mortality benefits expected from the back half of 2028.
- Grow Integrated Kidney Care
- More value-based contracts in CKCC and Medicare Advantage, and a CKD program with Humana covering approximately 10,000 CKD patients.
- Technology modernisation
- More than $1 billion invested over recent years to modernize the technology platform; tech spend grew more than 20% year-over-year and its growth will decelerate.
- Growth through de novos and international
- With the U.S. described as consolidated, growth comes more from new centers; international adjusted operating income is expected at approximately $135 million for 2026.
- Capital return within leverage target
- Share buybacks ($870 million in the first nine months of 2026) with leverage kept within a 3.0x-3.5x target.
Latest results
In Q3 2026 consolidated revenues were $3,578 million, adjusted operating income $561 million and net income attributable to DaVita Inc. $222.9 million, with diluted net income per share of $3.40 vs $2.04 in Q3 2025. For the first nine months revenues were $10,548 million (+5.2%) and adjusted operating income $1,622 million (+7.6%). U.S. dialysis revenue per treatment was $415.25 in Q3, pressured by lower commercial mix after enhanced ACA premium tax credits expired. Full-year 2026 guidance was narrowed to $2.175-$2.25 billion of adjusted operating income and $14.30-$15.20 of adjusted EPS, with free cash flow of $1 billion to $1.25 billion.
Investments and deals
- Elara Caring minority stake
- A $200 million minority investment in Elara Caring (home health, hospice, behavioral health and personal care), effective July 20, 2026, to offer dialysis-tailored home health services.
- Technology platform
- More than $1 billion invested to modernize technology, with benefits cited in mortality, revenue operations, labor productivity, IKC care management and pharmacy costs.
- Share repurchases
- $1,788 million of buybacks in FY2025 (14.9% net share count reduction) and $870 million in the first nine months of 2026; Berkshire Hathaway sells shares back to stay at 45.0%.
- Mozarc Medical
- A 50% kidney device venture with Medtronic; 2025 equity losses included $46.4 million of impairment and restructuring charges.
Challenges and risks
- Commercial payor mix
- Expiry of enhanced ACA premium tax credits hurt exchange enrollment and commercial mix: a $40 million headwind in 2026 and an expected $70 million in 2027.
- Reimbursement below cost trends
- CMS's 2027 final rule estimates a 2.7% average increase, but the CFO estimates a net 1.5%-2% impact; 90% of patients are government-covered.
- Labor costs and union activity
- Clinical labor wage rates rose approximately 3.8% in 2025, skilled clinical staff are short nationwide, and union petitions remain at California clinics.
- Cybersecurity
- An April 2025 incident exfiltrated PII and PHI, disrupted billing and new-patient intake, and cost approximately $25 million of charges in 2025.
- Demand and competition
- GLP-1 and SGLT2 therapies may slow CKD progression; competitors include Fresenius Medical Care and private-equity backed providers.
What leadership says
“a key milestone in our path back to 2% or greater volume growth by 2029”
“we've invested more than $1 billion to modernize our technology platform”
“we are part of the solution, not the problem.”
“The net result is a rate increase that once again tracks below the cost trends for the industry.”
Where a supplier can help
- Clinical labor productivity
- Tied to the labor cost challenge: staffing, scheduling and training tools for a labor-intensive network of about 2,657 U.S. centers.
- Cybersecurity and data protection
- Tied to the April 2025 incident that exfiltrated PII and PHI: security, monitoring and resilience for billing and patient intake systems.
- Revenue cycle and payor analytics
- Tied to the commercial payor mix challenge and the technology modernisation priority: collections, eligibility and payor-mix analytics.
- Value-based care tooling
- Tied to the IKC growth priority: predictive analytics, care coordination and claims analysis for CKCC, Medicare Advantage and the Humana CKD program.
- Dialysis supplies and devices
- Tied to the expanded HD rollout: dialyzers, medical supplies and logistics as patient care costs per treatment rise.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like DaVita Kidney Care?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- DaVita Inc. Annual Report on Form 10-K for fiscal year 2025
- DaVita is a comprehensive kidney care provider and a leading US dialysis provider: 2,657 US outpatient dialysis centers in 46 states and DC serving approximately 200,500 patients, inpatient dialysis contracts with approximately 740 hospitals, and an estimated approximately 36% share of the US dialysis market (Dec 31, 2025).
- FY2025 consolidated revenues were $13,643 million (+6.5%); operating income $2,044 million and adjusted operating income $2,094 million (+5.7%); net income attributable to DaVita Inc. $746.8 million; diluted net income per share $9.84; free cash flow $1,024 million.
- U.S. dialysis is approximately 86% of consolidated revenues ($11,793 million, +3.5%); revenue per treatment rose $18.24 to $409.56, mainly from the incorporation of phosphate binders into the ESRD PPS bundle, while treatments fell 1.1% on higher mortality and missed treatments from a more severe flu season.
- Payor economics: government programs give approximately 68% of U.S. dialysis patient service revenues for approximately 89% of patients; non-hospital commercial payors give approximately 26% of revenues for approximately 11% of patients, and commercial payors "generate nearly all of our profits".
- Ancillary services (U.S. IKC, U.S. other ancillary, international) were $1,922 million (+27.3%, approximately 14% of revenues); international operates 585 centers in 14 countries serving approximately 94,500 patients; IKC turned to $22 million operating income from a $(18) million loss.
- Capital allocation: 12,678,623 shares repurchased for $1,788 million (14.9% net share count reduction); leverage kept within the 3.0x-3.5x target; Berkshire Hathaway sells shares back quarterly to stay at 45.0%.
- An April 2025 cybersecurity incident exfiltrated PII and PHI, disrupted billing and new-patient intake, and cost approximately $25 million of charges in 2025, excluding business interruption.
- 2026 expectations in the filing: approximately flat U.S. treatment volumes, operating income growth from revenue per treatment partly offset by the expiry of enhanced ACA premium tax credits, growth in international and IKC; approximately 78,000 teammates (72% in the U.S.).
- DaVita Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 consolidated revenues $3,578 million; operating income $499 million and adjusted operating income $561 million; net income attributable to DaVita Inc. $222.9 million and diluted net income per share $3.40 (Q3 2025: $2.04).
- Nine months 2026: revenues $10,548 million (+5.2%), adjusted operating income $1,622 million (+7.6%), free cash flow $672 million, 5,837 thousand shares repurchased for $870 million.
- U.S. dialysis Q3: revenues $3,050 million, operating income $544 million; revenue per treatment $415.25, patient care costs per treatment $280.22; nine-month revenue per treatment +2.7% to $416.22.
- Expiry of enhanced ACA premium tax credits "has had an adverse impact" on exchange enrollment and commercial mix, pressuring revenue per treatment.
- IKC now covers approximately 80,800 patients in risk-based arrangements; nine-month IKC operating income $24 million versus a $(24) million loss.
- International: 598 centers in 14 countries; a $62 million goodwill and other asset impairment on the China business ($34 million attributable to minority interests).
- DaVita expects to offer expanded hemodialysis to the vast majority of eligible patients in November 2026; it closed a $200 million minority stake in Elara Caring effective July 20, 2026.
- CMS's 2027 final rule estimates a 2.7% average reimbursement increase; HHS released a 2026 Kidney Care National Plan on October 20, 2026, to promote competition, ease transplantation and move upstream.
- DaVita Q3 2026 earnings call transcript
- Q3 2026 adjusted operating income $561 million, adjusted EPS $3.82 and free cash flow $276 million; full-year 2026 guidance narrowed to $2.175-$2.25 billion adjusted operating income and $14.30-$15.20 adjusted EPS; free cash flow still $1-$1.25 billion.
- Expanded HD national rollout starting the week after the call: pilots in 150 centers for more than 10,000 patients, adoption above 90% of eligible patients, over 95% of clinical teammates trained; no material net impact on adjusted operating income in 2026 or 2027, benefits from lower mortality from the back half of 2028.
- Rodriguez calls expanded HD a key milestone on the "path back to 2% or greater volume growth by 2029".
- IKC now expected to deliver at least $65 million of adjusted operating income in 2026, up at least $25 million on prior guidance; a Humana partnership extends upstream care to approximately 10,000 CKD patients.
- More than $1 billion invested over recent years to modernize technology; tech spend grew more than 20% year-over-year and growth will decelerate.
- CMS 2027 rule: headline rate up 3.5% for large dialysis organizations, but CFO Joel Ackerman estimates a net 1.5%-2% impact for 2027; 1% of Medicare rate is worth about $30 million a year.
- Rodriguez backs most of HHS's Kidney Care National Plan but objects to how dialysis was portrayed, arguing 90% government mix with roughly 1% Medicare increases needs the government to "pay more".
- DaVita Q2 2026 earnings call transcript
- Q2 2026 adjusted operating income $579 million, adjusted EPS $4.02 and free cash flow $256 million; 2026 guidance reconfirmed at midpoints of $2.2 billion adjusted operating income and $14.65 adjusted EPS.
- Volume growth accelerated on improving mortality: treatments +56 basis points versus Q2 2025; 2026 treatment growth now expected near the top of the 25-50 basis point range.
- Revenue per treatment fell approximately $2 sequentially on lower commercial mix from declining ACA enrollment and lower phosphate binder revenue; full-year RPT growth still guided at 1%-2%; ACA headwind $40 million in 2026 and $70 million in 2027.
- After the MOTheR trial showed expanded HD non-inferior to HDF, DaVita secured supply of new Nipro expanded HD dialyzers to deploy across its network; no significant financial effect until mortality benefits from 2028.
- Rodriguez calls middle-molecule clearance a key building block toward "treatment volume growth of at least 2% by 2029".
- Closed a $200 million minority investment in Elara Caring in July; leverage 3.37x within a 3-3.5x target; Berkshire kept near 45%.
- On M&A, Rodriguez says the U.S. "is pretty consolidated now" and growth will come more from de novos.
Questions about DaVita Kidney Care
What does DaVita do?
DaVita provides kidney care, mainly dialysis for patients with end stage kidney disease in U.S. outpatient centers, hospitals and at home, plus integrated kidney care and international dialysis operations.
What is DaVita's revenue?
FY2025 consolidated revenues were $13,643 million, up 6.5%. Revenues for the first nine months of 2026 were $10,548 million, up 5.2%.
How many employees does DaVita have?
Approximately 78,000 teammates at December 31, 2025, about 72% of them in the U.S.
Who leads DaVita?
Javier Rodriguez is Chief Executive Officer and Joel Ackerman is CFO.
What is DaVita's strategy?
Return to treatment volume growth of 2% or more by 2029 through clinical innovation such as expanded HD, grow integrated kidney care, modernize technology and expand through de novos and international centers.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)